Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A dermatologist prescribed 0.625mg of oral minoxidil daily without a DHT blocker, which some users disagree with, suggesting a combination with finasteride or dutasteride for better results. Others argue starting with a low dose of minoxidil is standard to test tolerance before considering additional treatments.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

Switching from topical to oral minoxidil caused prolonged hair shedding without regrowth, leading to the use of both topical and oral minoxidil with oral finasteride. Responses to these treatments vary, emphasizing the need for personalized approaches.

A 25-year-old male has been using oral finasteride and minoxidil for six months without noticeable progress in hair regrowth and is considering switching to dutasteride or a hair transplant. Users suggest giving the treatment more time, adding microneedling, and possibly using topical minoxidil.

The user has used oral Dutasteride and Minoxidil for two years without regrowth, despite trying Finasteride and supplements. They consider increasing Minoxidil, adding microneedling, and switching medications, while others suggest RU58841, a hair transplant, or checking for other hair loss causes.

Reducing scalp DHT doesn't directly correlate with preventing hair miniaturization, as different follicles have varying sensitivity levels. Dutasteride at 0.5 mg and 2.5 mg shows minimal visual difference in hair regrowth, with side effects being a consideration for higher doses.

Topical finasteride that doesn't penetrate the skin could potentially treat hair loss without side effects. Current challenges include finding a formulation that remains on the scalp without increasing blood levels.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

People are discussing if microneedling alone can improve hair loss without using treatments like minoxidil, finasteride, or RU58841. Some users report moderate success with microneedling and natural remedies, but most suggest that results are better when combined with medical treatments.

The conversation discusses the complexity of reversing hair loss and the need for a treatment that specifically targets DHT levels without affecting other bodily functions. It mentions finasteride as a current treatment but highlights the desire for a solution that works solely on the scalp.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.

Japanese scientists discovered ABM cells, enabling successful human hair follicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The user has been using oral Dutasteride, RU58841, and Minoxidil for three years without success and is considering adding topical Finasteride or Dutasteride to target DHT both locally and systemically. Other users suggest sticking to a consistent treatment plan, exploring different combinations, and considering other factors like potential misdiagnosis or inconsistent medication use.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

A user shared their successful hair transplant experience with 2500 grafts by Dr. Ko in Korea, costing $8.7K, and mentioned using dutasteride and minoxidil post-surgery without side effects. The results were praised for looking natural, though some users questioned the graft count and photo authenticity.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.

Prostaglandin balance affects hair loss, particularly in conditions like Lichen Planopilaris, where an imbalance can lead to hair follicle damage. Treatments mentioned include prostaglandin analogs and Pioglitazone HCL, with a focus on maintaining prostaglandin equilibrium for potential hair regrowth.

RU58841 and topical GHK-CU are used together for hair loss, with RU58841 reducing shedding and GHK-CU improving scalp health. Users report noticeable hair growth and improved hair quality within weeks, especially when used consistently.

Switching from topical to oral minoxidil showed noticeable hair improvement, especially at the crown, within a few months. The user is considering increasing the oral dose and stopping the topical finasteride/minoxidil combo.

Topical Dutasteride, especially in a liposomal base, is recommended for enhanced scalp DHT suppression when used with oral Dutasteride. It is suggested to apply it twice a week for effective results without significant systemic impact.

Using tretinoin with minoxidil may improve absorption but results vary; some users see improved follicle growth while others notice no significant difference. Applying tretinoin before minoxidil is suggested by some users.

A 23-year-old male has been using finasteride and topical minoxidil for 14 months with slight improvement, but recent shedding led him to switch to a new minoxidil formulation without success. He is considering using topical RU58841 or dutasteride to better address scalp DHT, as his bloodwork shows high total testosterone and mid-range DHT levels.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.

Finasteride improved hair density and changed hair texture from wavy to curly for the user. The user took 1mg of oral finasteride daily without using minoxidil.

PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.